Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC2691
Dyslexia can be related to hereditary factors or other factors that affect brain development. Diagnosis of dyslexia involves reviewing the child's processing of information from seeing, hearing, and participating in activities.
Market Dynamics
Dyslexia can some time be related to hereditary where the child has difficulty in learning due to less brain development. A staggering 5 to 15 percent of Americans 14.5 to 43.5 million children and adults have dyslexia a learning disability that makes it difficult to read, write, and spell, no matter how hard the person tries or how intelligent he or she is. Noticeable rise in number of patients suffering from, dyslexia is pressurizing the government to take effective measures in order to tackle the situation. The National Center on Improving Literacy (NCIL) is a national center dedicated to increase access to, and use of, evidence-based approaches to screen, identify, and teach students with literacy-related disabilities, including dyslexia. In 2014, Tennessee’s House Bill 1735, was passed the bill follows a long history of legislative initiatives that have been designed to provide various legal protections for individuals with dyslexia. In 2015, 28 states had statewide dyslexia laws, 6 states had initiatives or resolutions related to dyslexia, and 14 states had handbooks or resource guides to inform parents and educators about proper procedures for students in public and private educational settings.
Increase in investment by major players for development of novel drugs in order to aid in treatment of patients suffering from dyslexia. Their approach towards enhancing the business through new product launch is expected to impact the growth of dyslexia drugs market.
In 2020, Dr Reddy’s Laboratories, a drug manufacturing company launched methylphenidate hydrochloride extended-release tablets in the US market. This product launch is expected to help the company to enhance the business in US.
In 2020, Zydus Cadila, a global drug manufacturer received approval from USFDA for Meclizine Hydrochloride tablets. This is expected to help the company to increasing its product offerings and enhance the customer base.
Major players approach towards enhancing the business in emerging economies in order to enhance the revenue share and rise in partnership activities to strengthen the distribution channel are factors expected to augment the target market growth. Factors such as stringent government regulations related to product approval and fluctuating raw material prices are factors expected to hamper the growth of global dyslexia drugs market. In addition, lack of developed infrastructure in developing countries for R&D activities is expected to challenge the growth of target market. However, increasing investment by major players for drug development and high government spending on healthcare infrastructure development are factors expected to create new opportunities for players operating in the dyslexia drugs market over the forecast period. In addition, increasing agreement activities between regional and international players is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global dyslexia drugs market due to rise in number of patients suffering from dyslexia. In addition, increasing government initiatives in order to provide enhance care to patient is expected to support the regional market growth. A number of states, however, have passed legislation that provides funds in the form of scholarships and grants as incentives for teachers to pursue additional training under the Dyslexia Education Scholarship Program. In 2015, the U.S. House Science, Space, and Technology Committee Chairman, Lamar Smith, introduced the Research Excellence and Advancements for Dyslexia Act (READ Act). The READ Act requires that the president’s annual budget include five million dollars of National Science Foundation funds to be allocated to dyslexia research.
Competitive Landscape
The global dyslexia drugs market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Dyslexia Drugs Market Segment Analysis, 2019
The end use segment of the global dyslexia drugs market is divided into hospital, clinics, and others. The hospital segment of the end use segment is expected to account for major revenue share in the global market. The players profiled in the report are GlaxoSmithKline, Pfizer, Sandoz International GmbH, Casper Pharma, Teva Pharmaceutical Industries Ltd., Actavis Labs, Inc., UCB S.A., Alkem Labs, Crescent Therapeutics Limited, Baxter, Intas Pharmaceuticals Ltd., and Brown & Burk.
Market Segmentation
Market By End Use
Hospital
Clinics
Others
Market By Geography
North America
• U.S.
• Canada
Europe
• U.K.
• Germany
• France
• Spain
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
Frequently Asked Questions
Increase in investment by major players for development of novel drugs in order to aid in treatment of patients suffering from dyslexia. Their approach towards enhancing the business through new product launch is expected to impact the growth of dyslexia drugs market.
In end use the clinics segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Pfizer, Sandoz International GmbH, Casper Pharma, and Teva Pharmaceutical Industries Ltd.
The North America is expected to account for major revenue share in the global market.
Factors such as stringent government regulations related to product approval and fluctuating raw material prices are factors expected to hamper the growth of global dyslexia drugs market.
